(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 5.72% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.54%.
Amneal Pharmaceuticals's revenue in 2026 is $3,045,859,000.On average, 8 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,008,750,068,304, with the lowest AMRX revenue forecast at $958,982,512,752, and the highest AMRX revenue forecast at $1,047,989,871,720. On average, 8 Wall Street analysts forecast AMRX's revenue for 2027 to be $1,084,358,470,008, with the lowest AMRX revenue forecast at $1,018,639,774,856, and the highest AMRX revenue forecast at $1,130,935,797,640.
In 2028, AMRX is forecast to generate $1,165,071,236,384 in revenue, with the lowest revenue forecast at $1,058,198,601,064 and the highest revenue forecast at $1,235,256,250,624.